Cognitive correlates of psychosis in patients with Parkinson's disease

Moustafa, Ahmed A.; Krishna, Rakhee; Frank, Michael J.; Eissa, Abeer M.; Hewedi, Doaa H.

doi:10.1080/13546805.2013.877385

Cited by 15 publications

(9 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Greater memory deficits have also been found for black-and-white visual stimuli than for coloured visual stimuli, perhaps reflecting more-limited encoding of visually impoverished stimuli in patients with visual hallucinations 47 . A transitive inference test thought to measure hippocampal function has uncovered impairments in patients with PD psychosis 48 .…”

Section: Mechanisms and Risk Factorsmentioning

confidence: 99%

The psychosis spectrum in Parkinson disease

et al. 2017

View full text Add to dashboard Cite

In 2007, the clinical and research profile of illusions, hallucinations, delusions and related symptoms in Parkinson disease (PD) was raised with the publication of a consensus definition of PD psychosis. Symptoms that were previously deemed benign and clinically insignificant were incorporated into a continuum of severity, leading to the rapid expansion of literature focusing on clinical aspects, mechanisms and treatment. Here, we review this literature and the evolving view of PD psychosis. Key topics include the prospective risk of dementia in individuals with PD psychosis, and the causal and modifying effects of PD medication. We discuss recent developments, including recognition of an increase in the prevalence of psychosis with disease duration, addition of new visual symptoms to the psychosis continuum, and identification of frontal executive, visual perceptual and memory dysfunction at different disease stages. In addition, we highlight novel risk factors — for example, autonomic dysfunction — that have emerged from prospective studies, structural MRI evidence of frontal, parietal, occipital and hippocampal involvement, and approval of pimavanserin for the treatment of PD psychosis. The accumulating evidence raises novel questions and directions for future research to explore the clinical management and biomarker potential of PD psychosis.

show abstract

Section: Mechanisms and Risk Factorsmentioning

confidence: 99%

The psychosis spectrum in Parkinson disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The loss of dopaminergic (DA) neurons is responsible for the development of PD motor symptoms (Liu, 2006 ). DA therapies, such as L-DOPA and dopamine agonists, either have a short half-life or may induce psychiatric side effects (Olanow et al, 2004 ; Moustafa et al, 2014 ). These issues raise the urgent need for an alternative form of therapeutic intervention.…”

Section: Introductionmentioning

confidence: 99%

Adenosine A2A Receptor Blockade Prevents Rotenone-Induced Motor Impairment in a Rat Model of Parkinsonism

Fathalla

Soliman

Ali

et al. 2016

Front. Behav. Neurosci.

Self Cite

View full text Add to dashboard Cite

Pharmacological studies implicate the blockade of adenosine receptorsas an effective strategy for reducing Parkinson’s disease (PD) symptoms. The objective of this study is to elucidate the possible protective effects of ZM241385 and 8-cyclopentyl-1, 3-dipropylxanthine, two selective A2A and A1 receptor antagonists, on a rotenone rat model of PD. Rats were split into four groups: vehicle control (1 ml/kg/48 h), rotenone (1.5 mg/kg/48 h, s.c.), ZM241385 (3.3 mg/kg/day, i.p) and 8-cyclopentyl-1, 3-dipropylxanthine (5 mg/kg/day, i.p). After that, animals were subjected to behavioral (stride length and grid walking) and biochemical (measuring concentration of dopamine levels using high performance liquid chromatography, HPLC). In the rotenone group, rats displayed a reduced motor activity and disturbed movement coordination in the behavioral tests and a decreased dopamine concentration as foundby HPLC. The effect of rotenone was partially prevented in the ZM241385 group, but not with 8-cyclopentyl-1,3-dipropylxanthine administration. The administration of ZM241385 improved motor function and movement coordination (partial increase of stride length and partial decrease in the number of foot slips) and an increase in dopamine concentration in the rotenone-injected rats. However, the 8-cyclopentyl-1,3-dipropylxanthine and rotenone groups were not significantly different. These results indicate that selective A2A receptor blockade by ZM241385, but not A1 receptor blockadeby 8-cyclopentyl-1,3-dipropylxanthine, may treat PD motor symptoms. This reinforces the potential use of A2A receptor antagonists as a treatment strategy for PD patients.

show abstract

“…Sleep disorders occur in three quarters of autopsy-confirmed cases of dementia with Lewy bodies, but may not necessarily correlate with sleep satisfaction; in addition to attentional, executive functioning, and visuospatial impairments, the presence of impaired verbal learning helps identify prodromal dementia with Lewy bodies in patients with sleep disorders 41 . Moreover, it has been shown that the severity of psychotic symptoms in patients with Parkinson's disease is directly associated with the severity of cognitive impairment and sleep disturbances 42 .…”

Section: Discussionmentioning

confidence: 99%

Correlates of neuropsychiatric and motor tests with language assessment in patients with Lewy body dementia

Machado

Oliveira

Marin

et al. 2020

Arch. Clin. Psychiatry (São Paulo)

View full text Add to dashboard Cite

Background: Lewy body dementia (LBD) impairs performance in daily activities and affects motor, language and visuospatial tasks. Objective: We aimed to correlate neuropsychiatric and motor assessments with language and visual organization tests in LBD. Methods: Twenty-two patients with dementia with Lewy bodies and ten patients with Parkinson's disease dementia participated on a cross-sectional study that assessed cognition, functionality, caregiver burden, verbal fluency, the primer-level dictation section of the Boston Diagnostic Aphasia Examination (PLD-BDAE), the Hooper Visual Organization Test, the Neuropsychiatric Inventory and the Movement Disorder Society -Unified Parkinson's Disease Rating Scale. Results: Language and visuospatial test results followed motor impairment and general cognitive performance. Whereas visual organization did not predict performance in the PLD-BDAE, visuospatial abilities and verbal fluency were concurrently associated, suggesting that linguistic impairment in LBD may be attributed to neuropsychological components of cognition and language. Only visual organization was associated with behaviour, suggesting that neuropsychiatric symptoms associate with differential impairment of visual organization in comparison with language in LBD. Schooling did not affect visual organization or language test performance, while the length of dementia was negatively associated with visual organization and verbal fluency. Discussion: Though visual organization tests follow behaviour and motor performance in LBD, there is differential impairment regarding language skills.

show abstract

Cognitive correlates of psychosis in patients with Parkinson's disease

Abstract: Although hypothetical, our data may suggest that the hippocampus is a neural substrate underlying the occurrence of psychosis, sleep disturbance and cognitive impairment in PD patients.

Cited by 15 publications

References 101 publications

The psychosis spectrum in Parkinson disease

The psychosis spectrum in Parkinson disease

Adenosine A2A Receptor Blockade Prevents Rotenone-Induced Motor Impairment in a Rat Model of Parkinsonism

Correlates of neuropsychiatric and motor tests with language assessment in patients with Lewy body dementia

Contact Info

Product

Resources

About